Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High serum levels of B-lymphocyte stimulator are associated with clinical-pathological features and outcome in classical Hodgkin lymphoma.
Tecchio C, Nadali G, Scapini P, Bonetto C, Visco C, Tamassia N, Vassilakopoulos TP, Pangalis GA, Calzetti F, Nardelli B, Roschke V, Gottardi M, Zampieri F, Gherlinzoni F, Facchetti F, Pizzolo G, Cassatella MA. Tecchio C, et al. Br J Haematol. 2007 Jun;137(6):553-9. doi: 10.1111/j.1365-2141.2007.06615.x. Br J Haematol. 2007. PMID: 17539776 Free article.
Post-transplant cyclophosphamide in acute leukemia patients receiving more than 5/10 HLA-mismatched allogeneic hematopoietic cell transplantation from related donors: A study on behalf of the ALWP of the EBMT.
Wieczorek M, Labopin M, Castagna L, Brissot E, Socié G, Raiola AM, Angelucci E, Rodríguez AB, Yakoub-Agha I, Aljurf M, Crawley C, Mear JB, Musso M, Fanin R, Avenoso D, Turlure P, Tecchio C, Sanz J, Ciceri F, Nagler A, Mohty M. Wieczorek M, et al. Among authors: tecchio c. Am J Hematol. 2023 Feb;98(2):E41-E44. doi: 10.1002/ajh.26782. Epub 2022 Nov 30. Am J Hematol. 2023. PMID: 36398703 Free article. No abstract available.
Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin.
Todeschini G, Tecchio C, Meneghini V, Pizzolo G, Veneri D, Zanotti R, Ricetti MM, Solero P, April F, Perona G. Todeschini G, et al. Among authors: tecchio c. Leukemia. 1998 Feb;12(2):144-9. doi: 10.1038/sj.leu.2400912. Leukemia. 1998. PMID: 9519775 Clinical Trial.
95 results